Skip to content

Study · In vitro (cells) · 2020

1 result

Genetic Code Expansion Enables Site-Specific PEGylation of a Human Growth Hormone Receptor Antagonist through Click Chemistry.

Tamshen K, Wang Y, Jamieson SMF, Perry JK, Maynard HD

Bioconjugate chemistry2 Sept 2020Cited by 14 (Europe PMC)

PMID32786367 (opens in a new tab)PMCIDPMC8291075 (opens in a new tab)DOI10.1021/acs.bioconjchem.0c00365 (opens in a new tab)PepBankPUB-32786367
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In GHR-expressing Ba/F3 cells, pegvisomant had a half-maximal inhibitory concentration of 1289 nM versus 103.3 nM for the B2036-20 kDa PEG conjugate.

    In plain wordsIn lab tests, pegvisomant required a higher concentration for half-maximal inhibition than the B2036-20 kDa PEG conjugate.

    Peptide
    Pegvisomant
    Outcome
    IncreaseHalf-maximal inhibitory concentration
    Study

    n: not reported in source

    GHR-expressing Ba/F3 cells
    Comparator
    B2036-20 kDa PEG conjugate
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    IC50
    1289 nM
    pegvisomant
    IC50
    103.3 nM
    B2036-20 kDa PEG conjugate

    Source sentences

    Summary
    Notably, the B2036-20 kDa PEG conjugate has a molecular weight comparable to pegvisomant, while exhibiting a 12.5 fold improvement in half-maximal inhibitory concentration in GHR-expressing Ba/F3 cells (103.3 nM vs 1289 nM).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.